Pulmonx Corp(LUNG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,725 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
LUNG Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Pulmonx Corp (LUNG), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LUNG at 23.4/100 on a 32-signal composite quality model, placing it at rank #2,725 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (3.7) and balance sheet strength (5.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Pulmonx Corp reports quarterly revenue of $22.8M, net income of $-10.1M, free cash flow of $-5.2M. Top institutional holders of LUNG by reported 13-F value include PRIMECAP MANAGEMENT, MORGAN STANLEY, Soleus Capital Management, L.P., based on the most recent SEC filings. LUNG trades on the Nasdaq exchange and files with the SEC under CIK 1127537. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LUNG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pulmonx Corp directly from SEC EDGAR. Pulmonx Corp's 13F Pro composite quality score has ranged between 18 and 29 since 2021, currently 23.4 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$22.8M
Net Income
Q2 2026
$-10.1M
Free Cash Flow
Q2 2026
$-5.2M
ROIC
Q2 2026
-47.1%
D/E Ratio
Q2 2026
0.96
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+8.0% YoYNet Income
+4.2% YoYOperating Income
+7.0% YoYEPS (Diluted)
+7.6% YoYTotal Assets
-20.6% YoYTotal Debt
-7.8% YoYOp. Cash Flow
-2.7% YoYFree Cash Flow
+0.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $90.5M +8.0% | $83.8M +22.0% | $68.7M +28.0% | $53.7M +10.8% | $48.4M +47.9% | $32.7M |
| Net Income | $-54.0M +4.2% | $-56.4M +7.3% | $-60.8M -3.3% | $-58.9M -21.1% | $-48.7M -51.0% | $-32.2M |
| Operating Income | $-53.7M +7.0% | $-57.7M +6.8% | $-61.9M -5.6% | $-58.6M -24.0% | $-47.3M -46.3% | $-32.3M |
| EPS (Diluted) | $-1.33 +7.6% | $-1.44 +10.0% | $-1.60 -0.6% | $-1.59 -17.8% | $-1.35 +57.3% | $-3.16 |
| Total Assets | $129.3M -20.6% | $162.8M -8.4% | $177.8M -8.2% | $193.7M -17.6% | $235.2M -10.8% | $263.7M |
| Total Debt | $37.2M -7.8% | $40.4M +2.4% | $39.4M +126.2% | $17.4M -0.5% | $17.5M +0.8% | $17.4M |
| Operating Cash Flow | $-32.4M -2.7% | $-31.5M +16.1% | $-37.6M +16.6% | $-45.1M -8.9% | $-41.4M -35.1% | $-30.6M |
| Free Cash Flow | $-32.8M +0.5% | $-33.0M +14.1% | $-38.4M +17.2% | $-46.4M -3.0% | $-45.1M -42.8% | $-31.5M |
Get alerted when LUNG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Pulmonx Corp including:
Top Institutional Holders of LUNG
PRIMECAP MANAGEMENT CO/CA/
$6.0M4,612,331 shMORGAN STANLEY
$3.8M2,922,921 shSoleus Capital Management, L.P.
$3.6M2,788,323 shVANGUARD CAPITAL MANAGEMENT LLC
$2.1M1,630,219 shExodusPoint Capital Management, LP
$1.6M1,223,555 shAlmitas Capital LLC
$1.4M1,064,202 shBlackRock, Inc.
$1.1M882,490 shStonepine Capital Management, LLC
$1.1M815,436 shJANE STREET GROUP, LLC
$985.7K758,231 shBRAIDWELL LP
$978.3K752,541 sh
| Fund | Value | Shares |
|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | $6.0M | 4,612,331 |
| MORGAN STANLEY | $3.8M | 2,922,921 |
| Soleus Capital Management, L.P. | $3.6M | 2,788,323 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.1M | 1,630,219 |
| ExodusPoint Capital Management, LP | $1.6M | 1,223,555 |
| Almitas Capital LLC | $1.4M | 1,064,202 |
| BlackRock, Inc. | $1.1M | 882,490 |
| Stonepine Capital Management, LLC | $1.1M | 815,436 |
| JANE STREET GROUP, LLC | $985.7K | 758,231 |
| BRAIDWELL LP | $978.3K | 752,541 |
Companies Similar to LUNG
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
NeuroPace Inc
TREACE MEDICAL CONCEPTS, INC.
CASTLE BIOSCIENCES INC
ORASURE TECHNOLOGIES INC
Karyopharm Therapeutics Inc.
ADC Therapeutics SA
EXAGEN INC.
ORTHOPEDIATRICS CORP
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put LUNG on your watchlist
Track score changes the day Pulmonx Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LUNG a good stock to buy?
13F Pro's AI-powered analysis of Pulmonx Corp (LUNG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LUNG are available on the LUNG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LUNG is classified as a small company.
Which hedge funds own LUNG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LUNG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Pulmonx Corp's investment landscape.